NASDAQ: ACRV
Acrivon Therapeutics Inc Stock Ownership - Who owns Acrivon Therapeutics?

Insider buying vs selling

Have Acrivon Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Peter BlumejensenPresident and CEO2026-05-2113,729$1.79
$24.57kSell
Erick GamelinChief Development Officer2026-05-14404$1.92
$775.68Sell
Katharine PetersonChief Accounting Officer2026-05-1499$1.92
$190.08Sell
Peter BlumejensenPresident and CEO2026-05-141,253$1.92
$2.41kSell
Peter BlumejensenPresident and CEO2026-05-14490$1.92
$940.80Sell
Eric DevroeChief Operating Officer2026-05-14613$1.92
$1.18kSell
Mary MillerChief Legal Officer2026-05-14184$1.92
$353.28Sell
Ra Capital Management LPDirector2026-04-223,888,888$1.80
$7.00MBuy
Mary MillerChief Legal Officer2026-04-17558$1.78
$993.24Sell
Peter BlumejensenPresident and CEO2026-02-2114,265$1.53
$21.83kSell

1 of 4

ACRV insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ACRV insiders and whales buy or sell their stock.

ACRV Shareholders

What type of owners hold Acrivon Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Ra Capital Management LP19.49%8,340,508$13.34MInstitution
Chione Ltd8.99%3,848,632$6.16MInsider
Kristina Masson8.62%3,691,232$5.91MInsider
Perceptive Advisors LLC7.25%3,104,139$4.97MInsider
Peter Blumejensen6.84%2,925,658$4.68MInsider
Sands Capital Alternatives LLC4.96%2,122,605$3.40MInstitution
Wellington Management Group LLP2.07%888,130$1.42MInstitution
Wellington Biomedical Innovation Master Investors Cayman I LP2.07%888,130$1.42MInsider
Acadian Asset Management LLC1.98%845,973$1.35MInstitution
Renaissance Technologies LLC1.77%758,440$1.21MInstitution

1 of 3

ACRV vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ACRV37.93%35.92%Net BuyingNet Buying
BYSI14.55%11.14%Net Selling
MNOV10.98%88.78%
ANVS13.63%15.18%Net BuyingNet Buying
ENTX15.99%16.15%Net BuyingNet Buying

Acrivon Therapeutics Stock Ownership FAQ

Who owns Acrivon Therapeutics?

Acrivon Therapeutics (NASDAQ: ACRV) is owned by 37.93% institutional shareholders, 35.92% Acrivon Therapeutics insiders, and 26.15% retail investors. Chione Ltd is the largest individual Acrivon Therapeutics shareholder, owning 3.85M shares representing 8.99% of the company. Chione Ltd's Acrivon Therapeutics shares are currently valued at $6.16M.

If you're new to stock investing, here's how to buy Acrivon Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.